Posts

Apnimed secures $192M upsized IPO to launch sleep apnea pill Oxnimbi

on

Caldera snaps up Synlogic in reverse merger to hit Nasdaq and fund IBD pipeline through 2029

on

Apnimed Targets Up to $160M IPO for Sleep Apnea Drug Oxnimbi Launch

on

Gene editor Scribe Therapeutics starts second-half IPO spree with $129M listing

on

There is always a first: Why US biotech Axiom will begin its IPO journey in Hong Kong

on

I&I startup Attovia files to go public as biotech listings momentum builds

on

Post-Hoc Live: What's making biotech IPOs work again?

on

Endevica spinout Kalohexis files confidential IPO to advance obesity drug rivaling GLP-1s

on

Scribe Therapeutics preps IPO to fund lipid‑lowering genetic medicines through clinical trials

on

UPDATED: Kardigan buttons up $400M upsized IPO to power heart drugs toward phase 3

on

Kardigan’s $320M IPO pitch: Three borrowed heart drugs, one proven cardio CEO

on

Parabilis’ record $670M IPO to fund cancer drug and platform expansion

on

Parabilis preps $413M IPO to fuel desmoid tumor drug into phase 3

on

Kardigan readies Nasdaq IPO to back three cardio drugs – latest news summary

on

Kardigan files for IPO to fund late‑stage cardiovascular pipeline

on

Parabilis reveals IPO plans the day after Regeneron deal as listings heat up

on

Odyssey Therapeutics Secures $279M IPO Amid Biotech Funding Challenges

on

CellCentric Raises $220M Series D to Advance Inobrodib Through Pivotal Trials in Multiple Myeloma, Eyes IPO

on

Hemab and Seaport Post Gains on NASDAQ After Raising $550M Across Their Debuts

on

Avalyn Pharma's Upsized $300M IPO Beats Expectations

on